KEGG   NETWORK: N10006Help
Entry
N10006                      Network                                

Name
Third-generation tyrosine kinase inhibitor to EGFR mutation
Definition
Osimertinib -| EGFR*
  Expanded
D10766 -| 1956v3
Class
nt06210 ERK signaling
nt06266 Non-small cell lung cancer
nt06214 PI3K signaling
Type
Drug target
Gene
1956  EGFR; epidermal growth factor receptor
Variant
1956v3  First generation TKI-resistant EGFR mutation
Perturbant
D10766  Osimertinib
Reference
  Authors
Mazza V, Cappuzzo F
  Title
Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.
  Journal
Appl Clin Genet 10:49-56 (2017)
DOI:10.2147/TACG.S103471
Reference
  Authors
Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Janne PA
  Title
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
  Journal
J Clin Oncol JCO2017747576 (2017)
DOI:10.1200/JCO.2017.74.7576

DBGET integrated database retrieval system